Skip to content

Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia

Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02350127
Acronym
PLIE-VA
Enrollment
88
Registered
2015-01-29
Start date
2015-05-04
Completion date
2018-12-31
Last updated
2020-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Dementia

Keywords

dementia, clinical trial, behavioral intervention, exercise, complementary and alternative medicine, cognition, function, quality of life

Brief summary

Nearly 1 in 10 older Veterans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status. Currently available dementia medications do not alter the disease course. Therefore, it is critically important to identify effective strategies for helping older Veterans living with dementia to enhance their functional status and quality of life. The investigators have developed a novel, integrative group movement program called Preventing Loss of Independence through Exercise (PLIE) that incorporates elements from Eastern and Western exercise modalities and is designed to build and maintain the capacity to perform basic functional movements while increasing mindful body awareness and enhancing social connection. Pilot study results suggested that PLIE is associated with meaningful improvements in physical function, cognitive function and quality of life as well as reduced caregiver burden. The goal of the current study is to perform a full-scale randomized, controlled trial to test the efficacy of PLIE in older Veterans with dementia.

Detailed description

The goal of the proposed study is to perform a randomized, controlled trial (RCT) to test the efficacy of a novel integrative group movement program called Preventing Loss of Independence through Exercise (PLIE) on function and quality of life in older Veterans living in the community with dementia. Dementia is a devastating condition that affects nearly 1 in 10 older Veterans (\ 1 million individuals). Current dementia medications have minimal impact on function and quality of life and do not stop or slow the disease course; however, there is growing evidence that behavioral interventions such as exercise have a variety of beneficial effects in individuals with dementia. PLIE was developed based on recent discoveries in neuroscience and experimental psychology that have found that, although explicit memory (the ability to consciously recall new information) is impaired in individuals with dementia, implicit memory (unconscious learning that typically occurs through repeated exposure) is relatively preserved. Therefore, PLIE focuses on training procedural memory (unconscious learning of procedures) to build the strength and capacity to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing). In addition, to maximize the benefits of the training, PLIE integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection. The investigators completed a pilot study of the PLIE program at an adult day center in San Francisco, CA, finding that it was associated with clinically meaningful improvements in cognitive function, physical performance and quality of life as well as reduced caregiver burden when compared with usual care at the facility. The current study will enable the investigators to build on these pilot study results by performing a full-scale RCT at adult day centers in Northern California. Most VA Medical Centers currently contract with community-based organizations to provide adult day care to eligible Veterans with dementia. Therefore, sites for the current study will be adult day centers that have current contracts with local VA medical centers. Within each center, study participants will be randomly assigned to receive the PLIE intervention program (1 hour, 2-3 days/week, 4 months) or Usual Care (UC) control (standard center activities, 1 hour, 2-3 days/week, 4 months) (N=120, 60/group) using a waitlist design. The co-primary outcomes are 4-month change in physical function (Short Physical Performance Battery, SPPB), cognitive function (Alzheimer's Disease Assessment Scale - cognitive subscale, ADAS-cog) and quality of life (Quality of Life in Alzheimer's Disease, QOL-AD). Changes in caregiver feelings (Caregiver Burden Inventory, CBI; Positive Aspects of Caregiving, PAC), mood (Geriatric Depression Scale, GDS), fear of falling (Falls Efficacy Scale, FES), independence (Disability Assessment for Dementia, DAD) and dementia-related behaviors (Neuropsychiatric Inventory, NPI) will be examined as secondary outcomes. To account for the waitlist design, all outcomes will be assessed at baseline, 4 months and 8 months. The proposed project will address a critically important Veterans' health problem related to optimizing functional status and quality of life in older Veterans with dementia. It is directly responsive to Request for Applications (RFA) RX-14-011 (RR&D Merit Review Award for Research on Amyotrophic Lateral Sclerosis, Parkinson's Disease and Alzheimer's Disease), which has identified pioneering new and innovative rehabilitation methodologies to restore function and improve quality of life for Veterans living with \[these\] neurodegenerative diseases as a major focus. Many patients and caregivers currently feel that little is being done to help individuals with dementia maintain function and quality of life. The current study will utilize rigorous research methods to test the efficacy of an innovative and promising new program for older adults with dementia. If the program is successful, the investigators will work with VA and community-based organizations to implement PLIE more broadly.

Interventions

PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.

BEHAVIORALUsual Care

Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.

Sponsors

LifeLong Marin Adult Day Health Center
CollaboratorOTHER
Institute on Aging, San Francisco, CA
CollaboratorOTHER
Catholic Charities
CollaboratorOTHER
Alzheimer's Services of the East Bay
CollaboratorOTHER
Bayview Hunters Point Adult Day Health Center
CollaboratorOTHER
Primrose Alzheimer's Living, Inc
CollaboratorOTHER
VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 120 dyads of individuals with dementia and their primary caregivers will be enrolled, with a goal of 20 dyads per intervention site. * Veterans with dementia will be prioritized for enrollment at each site. * Enrollment will be opened to non-Veterans with dementia at the site if there are not an adequate number of Veterans to fill the group. * Caregivers are not required to be Veterans, but their participation is necessary because they are providing care to the primary participants, many of whom will be Veterans. Inclusion criteria, primary participant: * diagnosis of memory loss or dementia * mild to moderate severity (defined as Clinical Dementia Rating of 0.5, 1 or 2) * English language fluency * attendance or willingness to attend adult day health center at least 2 days/week on days that PLIE will be offered Inclusion criteria, caregivers: * Provide care for primary participant * Able to answer study questionnaires related to participant's functional status, dementia-related behaviors, quality of life and their own burden. * English language fluency

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life Scale in Alzheimer's Disease (QOL-AD)4 monthsThe Quality of Life Scale in Alzheimer's Disease (QOL-AD) is a standard quality of life measure that asks parallel questions of affected individuals and caregivers. Current quality of life is rated as poor (1 point), fair (2 points), good (3 points) or excellent (4 points) in 13 areas: physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores around the house, ability to do things for fun, money, and life as a whole. Scores may range from 13 to 52 with higher scores reflecting better quality of life. Prior studies have found that the QOL-AD is a valid and reliable measure, with Cronbach's alpha of 0.84 for patient reports and 0.86 for caregiver reports and interrater reliability based on Cohen's kappa values \>0.70.
Short Physical Performance Battery (SPPB)-Modified4 monthsThe SPPB was developed by the National Institute on Aging to provide an objective tool for measuring physical performance in older adults. Lower body strength is assessed based on time to complete 5 chair stands without using arms. Balance is assessed based on the ability to hold different stands for 10 seconds, including the side-by-side, semi-tandem and full tandem stands. Mobility is assessed based on usual walking speed over a 3-meter walking course. The total SPPB score is the sum of the 3 component scores and may range from 0 to 12. Higher scores reflect better performance.
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)4 monthsThe Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) is one of the most commonly used outcome measures in dementia drug treatment trials and is one of the measures considered by the Food and Drug Administration for approval of dementia medications. It includes direct assessment of learning (10-word list), naming (objects), following commands, constructional praxis (figure copying), ideational praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions. Scores may range from 0 to 70 with higher scores reflecting worse cognitive function. Prior studies have found the ADAS-cog to be valid and reliable with Cronbach's alpha greater than 0.8 and test-retest reliability above 0.9.

Secondary

MeasureTime frameDescription
Neuropsychiatric Inventory - Frequency*Severity (NPI-FS)4 monthsThe Neuropsychiatric Inventory - Frequency\*Severity subscale (NPI-FS) assesses the frequency and severity of 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating) by caregiver report. NPI-FS was calculated by multiplying the frequency\*severity of behaviors, which had a range of 0-144. Higher scores indicate worse outcomes (greater frequency/severity).
Neuropsychiatric Inventory - Caregiver Distress4 monthsMeasure of caregiver distress associated with 12 common dementia-related behaviors. Scores may range from 0 to 60 with higher scores reflecting greater distress.
Quality of Life in Alzheimer's Disease - CG Report About Participant4 monthsCaregiver assessment of participant's quality of life. Scores may range from 13 to 52, with higher scores reflecting better quality of life.
Geriatric Depression Scale (GDS)4 monthsDepressive symptoms were assessed in caregivers based on self-report using the GDS - short form, a 15-item yes/no scale. Scores may range from 0 to 15, with higher scores reflecting greater depressive symptomatology.
Positive Aspects of Caregiving (PAC)4 monthsA standard measure that asks caregivers to rate their agreement/disagreement with 11 statements about positive aspects of caregiving on a 5-point likert scale (disagree a lot ... agree a lot). Total scores range from 11 to 55 with higher scores indicating more positive feelings
Caregiver Burden Inventory (CBI)4 monthsThe Caregiver Burden Inventory (CBI) is a standard measure that includes 24 items and 5 domains. Caregivers are asked to rate how often each statement describes their feelings (never, rarely, sometimes, quite frequently, nearly always). The total score may range from 0 to 96 with higher scores reflecting greater feelings of burden.
Balance Score4 monthsFrom Short Physical Performance Battery, including side-by-side, semi-tandem, and tandem balance. Score may range from 0 to 4, with higher scores indicating better balance.
Usual Gait Speed4 monthsFrom Short Physical Performance Battery, better of two times in seconds. Higher scores reflect worse (slower) performance.
Timed Up & Go4 monthsMeasure of mobility in which participant is timed while standing up from a seated position, walking around a cone that is 8 feet away, and returning to a seated position. Higher scores reflect worse (slower) performance.
Sit & Reach4 monthsMeasure of flexibility in which participant reaches toward toes with a straight leg. Score reflect closest to touching, with positive values reflecting past toes and negative values reflecting not touching toes.
Falls Efficacy Scale (FES) - Participant Report4 monthsA standard measure of falls efficacy that can be administered to people with cognitive impairment or caregivers and asks about concern about the possibility of falling doing 10 daily tasks (e.g., taking a bath or shower) on a 4-point likert scale (not at all, somewhat, fairly or very concerned). Scores may range from 10 to 40 with higher scores reflecting worse outcomes (i.e., greater concern about falling).
Chair Stand Time4 monthsTime to complete 5 chair stands without using arms in seconds. Higher scores reflect worse (slower) performance.
Disability Assessment for Dementia (DAD)4 monthsThe Disability Assessment for Dementia (DAD) is a standard measure of functional independence that asks caregivers whether the participant performed 17 basic and 23 instrumental activities of daily living over the past 2 weeks without reminder or assistance. Each item is rated as yes, no, or not applicable (i.e., never performed, no opportunity to perform). The score reflects the percent of items performed independently, excluding those that were not applicable. Therefore, scores may range from 0 to 100 with higher scores reflecting greater independence. The DAD has high established validity and high test-retest reliability (ICC, 0.96), inter-rater reliability (ICC, 0.95) and internal consistency (Cronbach's alpha, 0.96).
Neuropsychiatric Inventory - Number (NPI-N)4 monthsThe NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating). The NPI-N counts the number of symptoms present. Scores may range from 0 to 12 with higher scores reflecting worse outcomes (i.e., more symptoms).

Countries

United States

Participant flow

Participants by arm

ArmCount
Immediate Start
The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
44
Delayed Start
Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
44
Total88

Withdrawals & dropouts

PeriodReasonFG000FG001
4-Month AssessmentDeath10
4-Month AssessmentWithdrawal by Subject109
8-Month AssessmentDeath11
8-Month AssessmentWithdrawal by Subject58

Baseline characteristics

CharacteristicImmediate StartDelayed StartTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
43 Participants43 Participants86 Participants
Age, Categorical
Between 18 and 65 years
1 Participants1 Participants2 Participants
Age, Continuous80.0 years
STANDARD_DEVIATION 7.8
79.0 years
STANDARD_DEVIATION 7.3
79.5 years
STANDARD_DEVIATION 7.6
Participant MOCA Score10.7 units on a scale
STANDARD_DEVIATION 7.3
13.8 units on a scale
STANDARD_DEVIATION 6.9
12.3 units on a scale
STANDARD_DEVIATION 7.2
Race/Ethnicity, Customized
Race/Ethnicity
Asian
3 Participants1 Participants4 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Black/African American
3 Participants1 Participants4 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Hispanic/Latino (any race)
0 Participants2 Participants2 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Multiple/Other
0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Native Hawaiian/Pacific Islander
0 Participants1 Participants1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Non-Hispanic White
38 Participants38 Participants76 Participants
Region of Enrollment
United States
44 participants44 participants88 participants
Sex: Female, Male
Female
14 Participants15 Participants29 Participants
Sex: Female, Male
Male
30 Participants29 Participants59 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
2 / 441 / 44
other
Total, other adverse events
20 / 4412 / 44
serious
Total, serious adverse events
8 / 4410 / 44

Outcome results

Primary

Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)

The Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) is one of the most commonly used outcome measures in dementia drug treatment trials and is one of the measures considered by the Food and Drug Administration for approval of dementia medications. It includes direct assessment of learning (10-word list), naming (objects), following commands, constructional praxis (figure copying), ideational praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions. Scores may range from 0 to 70 with higher scores reflecting worse cognitive function. Prior studies have found the ADAS-cog to be valid and reliable with Cronbach's alpha greater than 0.8 and test-retest reliability above 0.9.

Time frame: 4 months

ArmMeasureValue (MEAN)Dispersion
Immediate StartAlzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)36.7 score on a scaleStandard Deviation 13.8
Delayed StartAlzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)30.4 score on a scaleStandard Deviation 13.2
Comparison: adjusting for baseline participant MOCA, robust VCEp-value: 0.795% CI: [-3.09, 2.08]Mixed Models Analysis
Primary

Quality of Life Scale in Alzheimer's Disease (QOL-AD)

The Quality of Life Scale in Alzheimer's Disease (QOL-AD) is a standard quality of life measure that asks parallel questions of affected individuals and caregivers. Current quality of life is rated as poor (1 point), fair (2 points), good (3 points) or excellent (4 points) in 13 areas: physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores around the house, ability to do things for fun, money, and life as a whole. Scores may range from 13 to 52 with higher scores reflecting better quality of life. Prior studies have found that the QOL-AD is a valid and reliable measure, with Cronbach's alpha of 0.84 for patient reports and 0.86 for caregiver reports and interrater reliability based on Cohen's kappa values \>0.70.

Time frame: 4 months

ArmMeasureValue (MEAN)Dispersion
Immediate StartQuality of Life Scale in Alzheimer's Disease (QOL-AD)38.8 score on a scaleStandard Deviation 6.2
Delayed StartQuality of Life Scale in Alzheimer's Disease (QOL-AD)40.0 score on a scaleStandard Deviation 4.3
Comparison: adjusted for participant baseline MOCA, robust VCEp-value: 0.1495% CI: [-0.59, 4.18]Mixed Models Analysis
Comparison: restricted to completersp-value: 0.0395% CI: [0.2, 5.6]Mixed Models Analysis
Primary

Short Physical Performance Battery (SPPB)-Modified

The SPPB was developed by the National Institute on Aging to provide an objective tool for measuring physical performance in older adults. Lower body strength is assessed based on time to complete 5 chair stands without using arms. Balance is assessed based on the ability to hold different stands for 10 seconds, including the side-by-side, semi-tandem and full tandem stands. Mobility is assessed based on usual walking speed over a 3-meter walking course. The total SPPB score is the sum of the 3 component scores and may range from 0 to 12. Higher scores reflect better performance.

Time frame: 4 months

ArmMeasureValue (MEAN)Dispersion
Immediate StartShort Physical Performance Battery (SPPB)-Modified6.1 score on a scaleStandard Deviation 3
Delayed StartShort Physical Performance Battery (SPPB)-Modified6.1 score on a scaleStandard Deviation 3.2
p-value: 0.6895% CI: [-1.23, 0.8]Mixed Models Analysis
Secondary

Balance Score

From Short Physical Performance Battery, including side-by-side, semi-tandem, and tandem balance. Score may range from 0 to 4, with higher scores indicating better balance.

Time frame: 4 months

ArmMeasureValue (MEAN)Dispersion
Immediate StartBalance Score2.4 score on a scaleStandard Deviation 1.4
Delayed StartBalance Score2.4 score on a scaleStandard Deviation 1.4
p-value: 0.5495% CI: [-0.4, 0.8]Mixed Models Analysis
Secondary

Caregiver Burden Inventory (CBI)

The Caregiver Burden Inventory (CBI) is a standard measure that includes 24 items and 5 domains. Caregivers are asked to rate how often each statement describes their feelings (never, rarely, sometimes, quite frequently, nearly always). The total score may range from 0 to 96 with higher scores reflecting greater feelings of burden.

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartCaregiver Burden Inventory (CBI)31.8 score on a scaleStandard Deviation 14.9
Delayed StartCaregiver Burden Inventory (CBI)32.0 score on a scaleStandard Deviation 14.9
p-value: 0.0295% CI: [0.8, 9.4]Mixed Models Analysis
Secondary

Chair Stand Time

Time to complete 5 chair stands without using arms in seconds. Higher scores reflect worse (slower) performance.

Time frame: 4 months

Population: Data missing for 10 immediate start and 13 delayed start participants (unable to complete test)

ArmMeasureValue (MEAN)Dispersion
Immediate StartChair Stand Time17.7 secondsStandard Deviation 8.4
Delayed StartChair Stand Time18.2 secondsStandard Deviation 9.8
p-value: 0.3595% CI: [-6.1, 2.1]Mixed Models Analysis
Secondary

Disability Assessment for Dementia (DAD)

The Disability Assessment for Dementia (DAD) is a standard measure of functional independence that asks caregivers whether the participant performed 17 basic and 23 instrumental activities of daily living over the past 2 weeks without reminder or assistance. Each item is rated as yes, no, or not applicable (i.e., never performed, no opportunity to perform). The score reflects the percent of items performed independently, excluding those that were not applicable. Therefore, scores may range from 0 to 100 with higher scores reflecting greater independence. The DAD has high established validity and high test-retest reliability (ICC, 0.96), inter-rater reliability (ICC, 0.95) and internal consistency (Cronbach's alpha, 0.96).

Time frame: 4 months

Population: Baseline data missing for 2 immediate start participants (1 did not have a caregiver, 1 caregiver did not complete questionnaire) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartDisability Assessment for Dementia (DAD)52.3 score on a scaleStandard Deviation 24.1
Delayed StartDisability Assessment for Dementia (DAD)65.5 score on a scaleStandard Deviation 23.9
p-value: 0.4795% CI: [-5.4, 11.6]Mixed Models Analysis
Secondary

Falls Efficacy Scale (FES) - Participant Report

A standard measure of falls efficacy that can be administered to people with cognitive impairment or caregivers and asks about concern about the possibility of falling doing 10 daily tasks (e.g., taking a bath or shower) on a 4-point likert scale (not at all, somewhat, fairly or very concerned). Scores may range from 10 to 40 with higher scores reflecting worse outcomes (i.e., greater concern about falling).

Time frame: 4 months

Population: Data missing for 1 immediate start and 1 delayed start participants (unable to answer questions).

ArmMeasureValue (MEAN)Dispersion
Immediate StartFalls Efficacy Scale (FES) - Participant Report14.2 score on a scaleStandard Deviation 6.7
Delayed StartFalls Efficacy Scale (FES) - Participant Report14.1 score on a scaleStandard Deviation 5.3
p-value: 0.0895% CI: [-3.9, 0.2]Mixed Models Analysis
Secondary

Geriatric Depression Scale (GDS)

Depressive symptoms were assessed in caregivers based on self-report using the GDS - short form, a 15-item yes/no scale. Scores may range from 0 to 15, with higher scores reflecting greater depressive symptomatology.

Time frame: 4 months

Population: Data missing for 2 immediate start participants (1 did not have a caregiver, 1 did not complete questionnaire) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartGeriatric Depression Scale (GDS)3.3 score on a scaleStandard Deviation 3.2
Delayed StartGeriatric Depression Scale (GDS)3.3 score on a scaleStandard Deviation 3
p-value: 0.07595% CI: [-1.7, 0.1]Mixed Models Analysis
Secondary

Neuropsychiatric Inventory - Caregiver Distress

Measure of caregiver distress associated with 12 common dementia-related behaviors. Scores may range from 0 to 60 with higher scores reflecting greater distress.

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartNeuropsychiatric Inventory - Caregiver Distress8.1 score on a scaleStandard Deviation 8.4
Delayed StartNeuropsychiatric Inventory - Caregiver Distress8.3 score on a scaleStandard Deviation 7.6
p-value: 0.895% CI: [-2.5, 3.3]Mixed Models Analysis
Secondary

Neuropsychiatric Inventory - Frequency*Severity (NPI-FS)

The Neuropsychiatric Inventory - Frequency\*Severity subscale (NPI-FS) assesses the frequency and severity of 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating) by caregiver report. NPI-FS was calculated by multiplying the frequency\*severity of behaviors, which had a range of 0-144. Higher scores indicate worse outcomes (greater frequency/severity).

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartNeuropsychiatric Inventory - Frequency*Severity (NPI-FS)15.9 score on a scaleStandard Deviation 18.4
Delayed StartNeuropsychiatric Inventory - Frequency*Severity (NPI-FS)14.1 score on a scaleStandard Deviation 15.9
p-value: 0.9895% CI: [-7.4, 7.2]Mixed Models Analysis
Secondary

Neuropsychiatric Inventory - Number (NPI-N)

The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating). The NPI-N counts the number of symptoms present. Scores may range from 0 to 12 with higher scores reflecting worse outcomes (i.e., more symptoms).

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartNeuropsychiatric Inventory - Number (NPI-N)4.0 score on a scaleStandard Deviation 2.8
Delayed StartNeuropsychiatric Inventory - Number (NPI-N)3.5 score on a scaleStandard Deviation 2.6
p-value: 0.9995% CI: [-1.1, 1.1]Mixed Models Analysis
Secondary

Positive Aspects of Caregiving (PAC)

A standard measure that asks caregivers to rate their agreement/disagreement with 11 statements about positive aspects of caregiving on a 5-point likert scale (disagree a lot ... agree a lot). Total scores range from 11 to 55 with higher scores indicating more positive feelings

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartPositive Aspects of Caregiving (PAC)36.9 score on a scaleStandard Deviation 8.2
Delayed StartPositive Aspects of Caregiving (PAC)39.5 score on a scaleStandard Deviation 9.5
p-value: 0.3595% CI: [-1.7, 5]Mixed Models Analysis
Secondary

Quality of Life in Alzheimer's Disease - CG Report About Participant

Caregiver assessment of participant's quality of life. Scores may range from 13 to 52, with higher scores reflecting better quality of life.

Time frame: 4 months

Population: Data missing for 1 immediate start participant (did not have a caregiver) and 1 delayed start participant (did not have a caregiver).

ArmMeasureValue (MEAN)Dispersion
Immediate StartQuality of Life in Alzheimer's Disease - CG Report About Participant31.2 score on a scaleStandard Deviation 5.6
Delayed StartQuality of Life in Alzheimer's Disease - CG Report About Participant33.1 score on a scaleStandard Deviation 5.1
p-value: 0.3895% CI: [-3.1, 1.2]Mixed Models Analysis
Secondary

Sit & Reach

Measure of flexibility in which participant reaches toward toes with a straight leg. Score reflect closest to touching, with positive values reflecting past toes and negative values reflecting not touching toes.

Time frame: 4 months

Population: Data missing for 3 immediate start and 2 delayed start participants (unable to complete test).

ArmMeasureValue (MEAN)Dispersion
Immediate StartSit & Reach-4.3 inchesStandard Deviation 5
Delayed StartSit & Reach-4.0 inchesStandard Deviation 4.2
p-value: 0.2695% CI: [-0.7, 2.5]Mixed Models Analysis
Secondary

Timed Up & Go

Measure of mobility in which participant is timed while standing up from a seated position, walking around a cone that is 8 feet away, and returning to a seated position. Higher scores reflect worse (slower) performance.

Time frame: 4 months

Population: Data missing for 2 immediate start and 3 delayed start participants (unable to complete test).

ArmMeasureValue (MEAN)Dispersion
Immediate StartTimed Up & Go15.7 secondsStandard Deviation 10.8
Delayed StartTimed Up & Go16.1 secondsStandard Deviation 18.1
p-value: 0.8895% CI: [-10.9, 9.3]Mixed Models Analysis
Secondary

Usual Gait Speed

From Short Physical Performance Battery, better of two times in seconds. Higher scores reflect worse (slower) performance.

Time frame: 4 months

Population: Data missing for 1 delayed start participant (unable to complete test).

ArmMeasureValue (MEAN)Dispersion
Immediate StartUsual Gait Speed5.6 secondsStandard Deviation 3.9
Delayed StartUsual Gait Speed5.6 secondsStandard Deviation 4.2
p-value: 0.6995% CI: [-1.5, 2.2]Mixed Models Analysis
Post Hoc

Satisfaction Score

Caregivers were sent an anonymous satisfaction survey after completion or withdrawal with a pre-paid return envelope. Satisfaction was rated on a 5-point Likert scale (1=Highly Unsatisfied to 5=Highly Satisfied). Open-ended questions asked about changes observed in study participants and themselves when participating in the program, what they liked the most and found most challenging, and other comments. Qualitative content analyses were performed to identify key domains and sub-domains described.

Time frame: 8 months

Population: 47 of 88 (53%) caregivers returned the survey

ArmMeasureValue (MEAN)Dispersion
Immediate StartSatisfaction Score4.5 score on a scaleStandard Deviation 0.9

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026